Musculoskeletal Ultrasound in Patients With Hematologic Malignancies
Musculoskeletal Ultrasonographic Findings in Patients With Hematologic Malignancies: A Diagnostic Imaging Study Protocol
This study evaluates the role and diagnostic value of musculoskeletal ultrasonography (MSUS) in adult patients with hematologic malignancies who present with musculoskeletal symptoms.
Hematologic malignancies (such as leukemia, lymphoma, and multiple myeloma) frequently involve the musculoskeletal system through bone marrow infiltration, bone destruction, or soft-tissue lesions. Musculoskeletal ultrasound is a non-invasive, radiation-free, and high-resolution imaging technique that allows real-time evaluation of joints, muscles, tendons, bursae, and superficial bone changes.
In this study, adult participants with confirmed blood cancers presenting with symptoms such as localized bone pain, joint swelling, muscle pain, or soft-tissue swelling will undergo a dedicated ultrasound examination of symptomatic areas. The study aims to characterize the patterns of musculoskeletal involvement (including cortical breaks, periosteal changes, soft-tissue masses, synovitis, and vascularity on Doppler imaging) and determine how these findings correlate with disease type, clinical presentation, and laboratory parameters.
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Adult patients (aged 18 years or older) with a confirmed diagnosis of hematologic malignancy (leukemia, lymphoma, or multiple myeloma) established by bone marrow examination, histopathology, and/or immunophenotyping.
- Patients presenting with musculoskeletal symptoms and undergoing musculoskeletal ultrasonography for the assessment of musculoskeletal involvement at diagnosis or during follow-up.
- Patients willing and able to provide written informed consent.
Exclusion Criteria:
- Patients with a prior or concurrent solid organ malignancy with known skeletal metastasis.
- Patients with a history of major musculoskeletal trauma, orthopedic surgery, or active musculoskeletal infection affecting the examined region.
- Patients with other connective tissue diseases (e.g., systemic lupus erythematosus, systemic sclerosis).
- Patients with other inflammatory arthropathies (e.g., psoriatic arthritis, ankylosing spondylitis, reactive arthritis).
- Patients with incomplete clinical, laboratory, or follow-up data.
- Patients who decline to participate or withdraw consent.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Patients with Hematologic Malignancies
Adult patients (aged 18 years or older) with a confirmed diagnosis of hematologic malignancy (leukemia, lymphoma, or multiple myeloma) who present with musculoskeletal symptoms (e.g., bone pain, joint pain/swelling, muscle pain, soft-tissue swelling, limitation of movement, or functional impairment) and undergo diagnostic musculoskeletal ultrasonography (MSK-US) with grayscale B-mode and color/power Doppler imaging to evaluate musculoskeletal involvement.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants with Abnormal Musculoskeletal Ultrasonographic Findings
Tijdsspanne: Baseline
|
The percentage of participants exhibiting at least one abnormal sonographic finding on B-mode and color/power Doppler musculoskeletal ultrasound in symptomatic regions.
Abnormal findings include cortical breaks/erosions, periosteal elevation/subperiosteal collections, focal soft-tissue or intramuscular masses/infiltrative lesions, joint effusion, synovial thickening/hypertrophy, tenosynovitis, or increased Doppler flow vascularity.
|
Baseline
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Neoplasmata per site
- Neoplasmata
- Gewrichtsziekten
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Leukemie, myeloïde
- Neoplasmata, plasmacel
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Hemorragische aandoeningen
- Sarcoom
- Neoplasmata, bindweefsel en zacht weefsel
- Hemische en lymfatische ziekten
- Leukemie
- Hematologische neoplasmata
- Lymfoom
- Multipel myeloom
- Musculoskeletale aandoeningen
- Sarcoom, myeloïde
- Synovitis
Andere studie-ID-nummers
- MSK Ultrasound in Blood Cancer
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .